Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D. Goldman, Philip C. Robinson, Thomas S. Uldrick, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002630-e002630
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Peter Bergman, Ola Blennow, Lotta Hansson, et al.
EBioMedicine (2021) Vol. 74, pp. 103705-103705
Open Access | Times Cited: 204
HIV and COVID-19: review of clinical course and outcomes
Lauren K. Barbera, Kevin Kamis, Sarah E. Rowan, et al.
HIV Research & Clinical Practice (2021) Vol. 22, Iss. 4, pp. 102-118
Open Access | Times Cited: 68
Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis
Alexandre R. Marra, Takaaki Kobayashi, Hiroyuki Suzuki, et al.
Journal of Infection (2022) Vol. 84, Iss. 3, pp. 297-310
Open Access | Times Cited: 56
COVID-19 convalescent plasma
Aaron A.R. Tobian, Claudia S. Cohn, Beth H. Shaz
Blood (2021) Vol. 140, Iss. 3, pp. 196-207
Open Access | Times Cited: 47
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease
Angelika Wagner, Erika Garner‐Spitzer, Anna‐Margarita Schötta, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 37
Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis
Nicole Hardy, Charan Thej Reddy Vegivinti, Mansi Mehta, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 6, pp. 1945-1959
Open Access | Times Cited: 19
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts
Karrie Kwan Ki Ko, Hatairat Yingtaweesittikul, Thuan Tong Tan, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 28
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
Lil Meyer-Arndt, Julian Braun, Florent Fauchère, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 9, pp. 960-971
Open Access | Times Cited: 28
SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
Béatrice Clémenceau, Thierry Guillaume, Marianne Coste‐Burel, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 448-448
Open Access | Times Cited: 27
NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins
Ilya Tsukalov, Ildefonso Sánchez‐Cerrillo, Olga Rajas, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings
Victor H. Ferreira, Javier T Solera, Queenie Hu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2
Pratima Saini, Opeyemi S. Adeniji, Devivasha Bordoloi, et al.
mBio (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Roopa Naik, Sreekant Avula, Sujith K Palleti, et al.
Cureus (2023)
Open Access | Times Cited: 11
Long COVID—ACOEM Guidance Statement
Gregg M. Stave, Ismail Nabeel, Quentin Durand‐Moreau
Journal of Occupational and Environmental Medicine (2024) Vol. 66, Iss. 4, pp. 349-357
Open Access | Times Cited: 4
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Heng Joo Ng, Maaz Kamal Alata, Quang The Nguyen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
Esther Saiag, Ayelet Grupper, Irit Avivi, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 5, pp. 735.e5-735.e8
Open Access | Times Cited: 19
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
Katherine E. Mues, Brenna Kirk, Deesha Patel, et al.
Vaccine (2022) Vol. 40, Iss. 47, pp. 6730-6739
Open Access | Times Cited: 18
Patient‐reported disruptions to cancer care during the COVID‐19 pandemic: A national cross‐sectional study
Jacob Lang, Aparna Narendrula, Sharanya Iyer, et al.
Cancer Medicine (2022) Vol. 12, Iss. 4, pp. 4773-4785
Open Access | Times Cited: 17
Decoding prognostic factors in SARS-CoV-2 complications among patients with hematological disorders
Fengbo Jin, Wei Qian, Yingying Chen, et al.
Clinics (2025) Vol. 80, pp. 100625-100625
Open Access
Memory T Cells in Respiratory Virus Infections: Protective Potential and Persistent Vulnerabilities
Henry Sutanto, Febrian Ramadhan Pradana, Galih Januar Adytia, et al.
Medical Sciences (2025) Vol. 13, Iss. 2, pp. 48-48
Open Access
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
Iwona Hus, Agnieszka Szymczyk, Joanna Mańko, et al.
Biology (2023) Vol. 12, Iss. 4, pp. 545-545
Open Access | Times Cited: 8
Healthcare resource utilisation and costs of hospitalisation and primary care among adults with COVID-19 in England: a population-based cohort study
Jingyan Yang, Kathleen M. Andersen, Kiran Rai, et al.
BMJ Open (2023) Vol. 13, Iss. 12, pp. e075495-e075495
Open Access | Times Cited: 8
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
Kévin Chevalier, Michaël Génin, Thomas Petit-Jean, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Considerations of CD8+ T Cells for Optimized Vaccine Strategies Against Respiratory Viruses
Toshiro Hirai, Yasuo Yoshioka
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top